Iron in Hodgkin's lymphoma

Critical Reviews in Oncogenesis

Volumn 18, Issue 5, 2013, Pages 463-469

  Hohaus, Stefan ^a   Giachelia, Manuela ^a   Cuccaro, Annarosa ^a   Voso, Maria Teresa ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anemia; Hepcidin; Hodgkin's lymphoma; Iron

Indexed keywords

ACUTE PHASE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; TRANSFERRIN RECEPTOR;

ANEMIA; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN SYNTHESIS; HODGKIN DISEASE; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON OVERLOAD; IRON RESTRICTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REED STERNBERG CELL;

ANEMIA; ANIMALS; CELLULAR MICROENVIRONMENT; FERRITINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPCIDINS; HODGKIN DISEASE; HUMANS; IRON; IRON OVERLOAD; RECEPTORS, TRANSFERRIN;

EID: 84880602600     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2013007765     Document Type: Article

References (51)

1. Giannopoulos PP, Bergsagel DE. The mechanism of the anaemia associated with Hodgkin's disease. Blood. 1959;14:856-69.
2. Haurani FI, Young K, Tocantins LM. Reutilization of iron in anemia complicating malignant neoplasms. Blood. 1963;22:73-81.
3. Beamish MR, Jones PA, Trevett D, Evans IH, Jacobs A. Iron metabolism in Hodgkin's disease. Br J Cancer. 1972;26:444-52.
4. Al-Ismail S, Cavill I, Evans IH, Jacobs A, Ricketts C, Trevett D,Whittaker JA. Erythropoiesis and iron metabolism in Hodgkin's disease. Br J Cancer. 1979;40:365-70.
5. Cartwright GE. The anemia of chronic disorders. Semin Hematol. 1966;3:351-75.
6. Cline MJ, Berlin NI. Anemia in Hodgkin's disease. Cancer. 1963;16:526-32.
7. Jones PA, Miller FM, Worwood M, Jacobs A. Ferritinaemia in leukaemia and Hodgkin's disease. Br J Cancer. 1973;27:212-7.
8. Jacobs A, Slater A, Whittaker JA, Canellos G, Wiernik PH. Serum ferritin concentration in untreated Hodgkin's disease. Br J Cancer. 1976;34:162-6.
9. Bezwoda WR, Derman DP, Bothwell TH, Baynes R, Hesdorffer C, MacPhail AP. Serum ferritin and Hodgkin's disease. Scand J Haematol. 1985;35:505-10.
10. Dörner MH, Abel U, Fritze D, Manke HG, Drings P. Serum ferritin in relation to the course of Hodgkin's disease. Cancer. 1983;52:2308-12.
11. Bieber CP, Bieber MM. Detection of ferritin as a circulating tumor-associated antigen in Hodgkin's disease. Natl Cancer Inst Monogr. 1973;36:147-57.
12. Eshhar Z, Order SE, Katz DH. Ferritin, a Hodgkin's disease associated antigen. Proc Natl Acad Sci U S A. 1974;71:3956-60.
13. Cazzola M, Arosio P, Gobbi PG, Barosi G, Bergamaschi G, Dezza L, Iacobello C, Ascari E. Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. Eur J Cancer Clin Oncol. 1983;19:339-45.
14. Singh S, Singh M, Kalra R, Marwah N, Chhabra S, Arora B. Transferrin receptor expression in reactive and neoplastic lesions of lymphnodes. Indian J Pathol Microbiol. 2007;50:433-6.
15. Bjerner J, Amlie LM, Rusten LS, Jakobsen E. Serum levels of soluble transferrin receptor correlate with severity of disease but not with iron stores in patients with malignant lymphomas. Tumour Biol. 2002;23:146-53.
16. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-33.
17. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, D'Alo' F, Larocca LM, Raymakers RA, Swinkels DW, Voso MT, Leone G. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol. 2010;28:2538-43.
18. Broxmeyer HE, Lu L, Bicknell DC, Williams DE, Cooper S, Levi S, Salfeld J, Arosio P. The influence of purified recombinant human heavy-subunit and light-subunit ferritins on colony form-ation in vitro by granulocyte-macrophage and erythroid progenitor cells. Blood. 1986;68:1257-63.
19. Broxmeyer HE, Williams DE, Geissler K, Hangoc G, Cooper S, Bicknell DC, Levi S, Arosio P. Suppressive effects in vivo of purified recombinant human H-subunit (acidic) ferritin on murine myelopoiesis. Blood. 1989;73:74-9.
20. Broxmeyer HE, Cooper S, Levi S, Arosio P. Mutated recombinant human heavy-chain ferritins and myelosuppression in vitro and in vivo: a link between ferritin ferroxidase activity and biological function. Proc Natl Acad Sci U S A. 1991;88:770-4.
21. Zucker S, Friedman S, Lysik RM. Bone marrow erythropoiesis in the anemia of infection, inflammation, and malignancy. J Clin Invest. 1974;53:1132-8.
22. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987-94.
23. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood. 1998;91:2139-45.
24. Pohl C, Schobert I, Moter A, Woll EM, Schwonzen M, Hiersche A, Diehl V. Serum erythropoietin levels in patients with Hodgkin's lymphoma at the time of diagnosis. Ann Oncol. 1992;3:172-3.
25. Good MF, Powell LW, Halliday JW. Iron status and cellular immune competence. Blood Rev.1988;2:43-9.
26. Weinberg JB, Hibbs JB Jr. Endocytosis of red blood cells or haemoglobin by activated macrophages inhibits their tumoricidal effect. Nature. 1977;269:245-7.
27. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875-85.
28. Hohaus S, Santangelo R, Giachelia M, Vannata B, Massini G, Cuccaro A, Martini M, Cesarini V, Cenci T, D'Alo F, Voso MT, Fadda G, Leone G, Larocca LM. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res. 2011;17:2885-92.
29. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011;96:269-76.
30. Sánchez-Aguilera A, Montalbán C, de la Cueva P, Sánchez-Verde L, Morente MM, García-Cosío M, García-Laraña J, Bellas C, Provencio M, Romagosa V, de Sevilla AF, Menárguez J, Sabín P, Mestre MJ, Méndez M, Fresno MF, Nicolás C, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group.Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108:662-8.
31. Allavena P, Sica A, Garlanda C, Mantovani A. The YinYang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155-61.
32. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198-201.
33. Ganz T. Macrophages and Systemic Iron Homeostasis. J Innate Immun. 2012;4:446-53.
34. Recalcati S, Locati M, Marini A, Santambrogio P, Zaninotto F, De Pizzol M, Zammataro L, Girelli D, Cairo G. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol. 2010;40:824-35.
35. Corna G, Campana L, Pignatti E, Castiglioni A,Tagliafico E, Bosurgi L, Campanella A, Brunelli S, Manfredi AA, Apostoli P, Silvestri L, Camaschella C, Rovere-Querini P. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica. 2010;95:1814-22.
36. Weiss, G. Iron metabolism in the anemia of chronic disease. Biochem Biophys Acta. 2009;1790:682-93.
37. Hazard JT, Drysdale JW. Ferritinaemia in cancer. Nature. 1977;265:755-6.
38. Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G. Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol. 1979;42:345-53.
39. Fargion S, Fracanzani AL, Brando B, Arosio P, Levi S, Fiorelli G. Specific binding sites for H-ferritin on human lymphocytes: modulation during cellular proliferation and potential implication in cell growth control. Blood. 1991;78:1056-61.
40. Gray CP, Franco AV, Arosio P, Hersey P. Immunosuppressive effects of melanoma-derived heavy chain ferritin are dependent on stimulation of IL-10 production. Int J Cancer 2001;92:843-50.
41. Yuen AR, Higgins JP, Baker R, Kamel OW, Warnke RA, Knox SJ. Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma. Hum Pathol. 2003;34:381-4.
42. Vriesendorp HM, Morton JD, Quadri SM. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res. 1995;55:5888s-5892s.
43. Yuan XM, Li W, Baird SK, Carlsson M, Melefors O. Secretion of ferritin by iron-laden macrophages and influence of lipoproteins. Free Radic Res. 2004;38:1133-42.
44. Wesselius LJ, Nelson ME, Skikne BS. Increased release of ferritin and iron by iron-loaded alveolar macrophages in cigarette smokers. Am J Respir Crit Care Med. 1994;150:690-5.
45. Rossiello R, Carriero MV, Giordano GG. Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol. 1984;37:51-5.
46. Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol. 2000;11:1105-14.
47. Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol. 2010;28:2239-45.
48. Ukarma L, Johannes H, Beyer U, Zaug M, Osterwalder B, Scherhag A. Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients. Clin Chem. 2009;55:1354-60.
49. Hedenus M, Birgegård G, Näsman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627-32.
50. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Lundin J, Lärfars G, Osterborg A. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008;26:1619-25.
51. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplant. 2008;14:1239-44.